Cart
sales@molnova.com
PDL-1 cpd 10
CAS No. 2767424-13-3
PDL-1 cpd 10( —— )
Catalog No. M37623 CAS No. 2767424-13-3
PDL-1 cpd 10 is a novel small molecule PD-L1 inhititor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 123 | In Stock |
|
| 5MG | 112 | In Stock |
|
| 10MG | 180 | In Stock |
|
| 25MG | 376 | In Stock |
|
| 50MG | 546 | In Stock |
|
| 100MG | 761 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NamePDL-1 cpd 10
-
NoteResearch use only, not for human use.
-
Brief DescriptionPDL-1 cpd 10 is a novel small molecule PD-L1 inhititor.
-
DescriptionPD-L1-IN-1 is a potent PD-L1 inhibitor with an IC50 of 115 nM. PD-L1-IN-1 strongly binds with the PD-L1 protein and challenged it in a co-culture of PD-L1 expressing cancer cells (PC9 and HCC827 cells) and peripheral blood mononuclear cells enhanced antitumor immune activity of the latter. PD-L1-IN-1 significantly increased interferon γ release and apoptotic induction of cancer cells, with low cytotoxicity in healthy cells.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayImmunology/Inflammation
-
TargetPD-1/PD-L1
-
RecptorPD-1/PD-L1
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2767424-13-3
-
Formula Weight377.44
-
Molecular FormulaC21H23N5O2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 125 mg/mL (331.18 mM; Ultrasonic (<60°C)
-
SMILESCC1=C(C=CC=C1COC=2N=C(NCCNC(C)=O)N=CN2)C3=CC=CC=C3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Russomanno P, et al. Interfering with the Tumor-Immune Interface: Making Way for Triazine-Based Small Molecules as Novel PD-L1 Inhibitors. J Med Chem. 2021;64(21):16020-16045. ?
molnova catalog
related products
-
BMS-1166 hydrochlori...
BMS-1166 is a potent PD-1/PD-L1 interaction inhibitor with IC50 of 1.4 nM in a homogenous time-resolved fluorescence binding assay.
-
Spartalizumab
Spartalizumab (PDR001) is a humanized immunoglobulin G4 monoclonal antibody that selectively binds to PD-1 at low concentrations, exhibiting high activity.
-
Pembrolizumab
Pertuzumab anti-HER2) a humanized monoclonal antibody and the first in the class of agents called the HER2 dimerization inhibitors impairs the ability of HER2 to bind to other members of the HER family.
